ArticleReports of biochemistry & molecular biology2025
Association of Haptoglobin Heterozygosity (HP1-2) with the Risk of COVID-19 Infection in a Sample of the Iranian Population.
Article in Reports of biochemistry & molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: COVID-19 is a highly contagious viral disease that primarily affects the respiratory system and occasionally the gastrointestinal system, and it was declared a pandemic in 2020. Haptoglobin is an acute-phase protein and a potent antioxidant in the body, which exerts its antioxidant effect by binding to free hemoglobin. Haptoglobin has three main variants (Hp1-1, Hp1-2, Hp2-2), each with different antioxidant capacities. The purpose of this study is to investigate frequency of the haptoglobin variants in COVID-19 patients compared to a control group. Methods: This study was conducted on 148 COVID-19 patients and 145 healthy individuals from the Sistan and Baluchestan province. DNA was isolated from whole blood using the salt precipitation method, and the determination of haptoglobin genotypes (Hp1-1, Hp1-2, and Hp2-2) was performed using Conventional PCR. Results: This study analyzed haptoglobin (HP) genotypes in COVID-19 patients and controls, finding no significant difference in HP variant frequencies between groups (p= 0.529). However, the HP1-2 genotype was associated with a twofold increased COVID-19 risk in men (OR=2.069, p= 0.021), and the HP1 allele significantly raised infection risk (OR= 1.62, p= 0.039). Hospitalizations and respiratory symptoms were significantly higher in COVID-19 patients (p= 0.0001 and p= 0.0176, respectively). Conclusions: These results suggest that haptoglobin variants are not risk factors for COVID-19 infection in the overall population (both males and females). However, men with the HP1-2 genotype are 1.9 times more likely to develop COVID-19 infection compared to men with HP1-1 and HP 2-2 genotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.